Interest of Morphokinetic Parameters of Early Embryonic Development in the Birth Rates in Vitro Fertilization (EMCIMO)

Do the Morphokinetic Parameters of Early Embryonic Development Have an Interest in the Choice of the Embryo to be Transferred and Improve Birth Rates in Vitro Fertilization

In France, nearly 3% of children are conceived by the technique of Assisted Reproductive Medicine, of which nearly 70% by in vitro fertilization (IVF). The rates of clinical pregnancy by oocyte retrieval or embryo transfer have not changed much. The use of mono-embryo transfer reduces the risk of multiple pregnancies and associated obstetric complications. The choice of embryo to transfer or freeze is a key element in improving the chances of success of IVF. It is usually based on conventional morphological criteria (reference method) that are punctual, qualitative and subjective. However, embryo morphology at early stages has little predictive value for obtaining a late-stage embryo and its chances of implantation. The recent use of time-lapse technology during embryonic culture makes it possible to associate morphological criteria with continuous monitoring of the kinetics of embryonic development. The choice of the embryo to be transferred is then made according to morphokinetic criteria (conventional morphological criteria to which are added the data of the kinetics of embryonic development).

Two recent retrospective studies give contradictory results, the first shows higher birth rates in the group of embryos selected according to conventional morphological criteria, the second concludes that morphokinetic analysis is superior. Morphokinetic criteria would also be more objective and reproducible. However, the use of morphokinetic parameters remains controversial in the literature.

Study Overview

• Status: Recruiting
• Conditions: Reproductive Disorder
• Intervention / Treatment: Other: Morphokinetic

• Study Type: Interventional
• Enrollment (Estimated): 520
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Caen, France, 14033
    • Recruiting
    • CHU Caen
    • Contact: Marie-Ange Clarotti, Dr; Phone Number: 02 31 06 45 55; Email: Clarotti-ma@chu-caen.fr
    • Sub-Investigator: Marie-Ange Clarotti, Dr
  • Rouen, France, 76031
    • Recruiting
    • CHU Rouen
    • Contact: Pierre Di Pizio, Dr; Phone Number: 02 32 88 82 25; Email: Pierre.di-pizio@chu-rouen.fr
    • Principal Investigator: Pierre Di Pizio, Dr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 59 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. For the couple:

   • Couple whose two members are 18 years old and over,
   • Couple whose two members are affiliated to a social security scheme,
   • Couple whose two members read and understood the newsletter and signed the consent form for their participation in this research.

2. For the conditions of realization of the ICSI attempt:

   • Couple supported for a 1st or 2nd attempt at in vitro fertilization with sperm microinjection (ICSI) for male infertility,
   • In vitro fertilization attempt performed with micro-injection of fresh ejaculated spermatozoa.

3. For the man:

   • Couple whose man has an alteration of at least one of the sperm parameters according to the WHO (WHO, 2010) for the number, concentration, vitality, mobility or morphology according to the modified David classification (Auger and Eustache, 2000).

Exclusion Criteria:

1. For the couple:

   • Couple whose wife is under 18 and over 42 and / or the male is under 18 and over 59
   • Couple already included in the protocol "EMCIMO" for a previous attempt,
   • Couple of which one or both members is deprived by an administrative or judicial decision or subject to a legal measure of protection of the majors (safeguard of justice or tutelage or curatorship),
   • Couple where one or both members do not speak or understand French.

2. For the conditions of realization of the ICSI attempt:

   - In vitro fertilization attempt with the micro-injection of testicular spermatozoa, epididymal, previously frozen or resulting from a retrograde ejaculation.

3. For the man:

   • Severe oligozoospermia (<100,000 spermatozoa / ejaculate).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Conventional morphology arm (reference method)	Other: Morphokinetic; The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).
Experimental: Morphokinetic arm	Other: Morphokinetic; The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The primary endpoint of this study will be the live birth rate by fresh embryo transfer(s).	36 months

Collaborators and Investigators

• Sponsor: University Hospital, Rouen

Study record dates

Study Major Dates

• Study Start (Actual): October 26, 2020
• Primary Completion (Estimated): June 1, 2029
• Study Completion (Estimated): June 1, 2029

Study Registration Dates

• First Submitted: January 14, 2019
• First Submitted That Met QC Criteria: January 15, 2019
• First Posted (Actual): January 16, 2019

Study Record Updates

• Last Update Posted (Actual): May 12, 2026
• Last Update Submitted That Met QC Criteria: May 7, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: 2017/0385/HP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No